%0 Journal Article
%T Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end
%A Christopher A Schriever
%A Melissa E Badowski
%A Sarah M Michienzi
%J International Journal of STD & AIDS
%@ 1758-1052
%D 2019
%R 10.1177/0956462418800865
%X No single-tablet antiretroviral (ARV) regimens (STRs) are approved for patients with human immunodeficiency virus (HIV) and end-stage renal disease (ESRD) on hemodialysis (HD). Based on known pharmacokinetic (PK) properties, abacavir (ABC)/lamivudine (3TC)/dolutegravir (DTG) STR may represent a promising option. This case series presents the safety and efficacy of ABC/3TC/DTG STR in patients with HIV and ESRD on HD. Patients were included if they were HIV-positive, maintained on intermittent HD for ESRD, switched to an ARV regimen containing ABC/3TC/DTG, and had at least one set of virologic data before and after the switch. Average age (”Ąstandard deviation) was 59 (”Ą8) years. The majority of patients were cis-gender male and non-Hispanic Black. Only one demonstrated clinically significant resistance at baseline. All were on multiple-tablet regimens prior to the switch. Five patients (83%) achieved undetectable HIV-RNA after the switch while only four patients (46%) were undetectable immediately prior. No decline in immune function was noted. ABC/3TC/DTG STR was well tolerated. Only one patient self-reported an adverse event (nausea), which resolved without drug discontinuation. Based on these data, it appears that ABC/3TC/DTG may be a safe and effective ARV-STR option for patients with HIV and ESRD on HD. A larger trial including a PK analysis is needed to confirm these findings
%K Combination antiretroviral therapy
%K antiretroviral therapy
%K treatment
%K human immunodeficiency virus
%K acquired immunodeficiency syndrome
%U https://journals.sagepub.com/doi/full/10.1177/0956462418800865